This pilot study focuses on how we measure certain side effects that may occur during and after taxane-based chemotherapy for breast cancer. Taxanes are widely used due to their effectiveness, but they can also cause significant adverse effects. One of these is chemotherapy-induced peripheral neuropathy (CIPN).

CIPN may present as numbness and/or tingling in the toes, feet, fingers, or hands. Some individuals may also report reduced sensitivity, hypersensitivity to certain stimuli, pain, sensory changes, and even balance disturbances. Despite the clinical importance of these symptoms, there are currently no clear guidelines to effectively assess, prevent, or slow the progression of CIPN.

​

The objective of this project is to examine the extent to which current tools accurately assess CIPN and to determine whether measurement results differ between younger and older individuals. Data were collected from adults with breast cancer at four time points along their care trajectory. During assessment visits, the research team gathered sociodemographic information, administered physical tests, and collected responses to self-reported questionnaires on symptoms and quality of life.

​

Thanks to the dedicated participation of study participants, this project will contribute to a better understanding of the quality of the tools currently used to assess CIPN.